# AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

> **NCT06991114** · PHASE2 · RECRUITING · sponsor: **Artiva Biotherapeutics, Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Refractory Rheumatoid Arthritis (RA)
- Idiopathic Inflammatory Myopathies (IIMs)
- Systemic Sclerosis (SSc)
- Rheumatoid Arthritis (RA
- IIM
- Myositis
- Scleroderma
- Sjogren Syndrome
- Sjogrens Disease

## Interventions

- **DRUG:** Allogeneic NK Cells

## Key facts

- **NCT ID:** NCT06991114
- **Lead sponsor:** Artiva Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-09
- **Primary completion:** 2028-01
- **Final completion:** 2029-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06991114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06991114, "AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06991114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*